1[1]Takano H,Kohno K,Matsuo K,et al.DNA topoisomerase-tergeting antitumor agents and drug resistance[ J ].Anticancer Drue,1992,3 (4):323-330.
2[2]Holm G,Wan YJ,Gabbert HE,et al.The Topol,Ⅱ in tumour[J].Cell,1994,49(3):553-556.
3[3]Uemura C,Gabbert HE,Jettent M.Inhibition of growth and squamous cell differentiation markers in culrured human head and neck squamous carcinoma cells[ J ].Cell,1993,48 (11):207-209.
4[4]Creemers GJ,Lund B,Verweij J.Topoisomerase I inhibitors:topotecan and irenotecan[ J ].Cancer Treament Reviews,1994,20(1):73-76.
5[5]Shuji S,Seiji S,Naito J.Increased expression of DNA topoisomerase Ⅰ gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells[ J ].Cancer Res,1994,54 (3):3248-3252.
6[6]Biran K,virsan J,Donald M.Reduces Topol Ⅱ in head Squamous carcinoma[J].Sinha Drug,1995,49(1):11-13.
7[7]Danks P,Pawlik M,Wipple L,et al.Topol Ⅱ gene expression in head and neck carcinoma[J].Clin Cancer Res,1997,3(10):1731-1738.
8[8]Beachesne B,Bonner M,Brunon-J.Sensitivity to eptoside of human malignant glioma cell lines[ J ].Cancer Radiother,1999,3 (1):57-64.
9[9]Verea N,Sant V,Vorrt T.Increased expression of Topol Ⅰ DNA in glioma[ J].Int J Cancer,1995,61 (2):375-380.
10[10]Eijden S,Brand J,Vernik M.Topol Ⅰ and Topol Ⅱ In brain cancer[J].Br J Cancer,1995,71 (2):40-47.
